Chronic pain ruins quality of life

PN6047 – a unique mode of action

PharmNovo’s mission is to discover new, safe, and effective drugs to help patients suffering from neuropathic pain. We combine innovative chemistry and bioscience to discover new treatments for neuropathic pain and other diseases of the nervous system.

Our drug candidate PN6047 is an agonist, a drug that binds to and activates a specific receptor. It is a potent, carefully developed, small molecule that selectively activates the delta (δ) opioid receptor (DOR).

PN6047 does not, like conventional opioids, affect the mu (μ) opioid receptor, which is known to provide adequate relief for acute pain, but also causes addiction and severe side effects, such as respiratory depression, abuse potential, itching and constipation.

Activating the delta receptor does not provide acute pain relief - but it produces an excellent reversal of neuropathic pain in animal models.

The approach of activating the delta receptor is entirely new. The underlying concept is to specifically activate the beneficial parts of the system while avoiding the type of activation that results in unwanted side effects.

Latest news

View all

PharmNovo live at neurology theme event at RedEye

October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.